We are comparing VBI Vaccines Inc. (NASDAQ:VBIV) and Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) on their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VBI Vaccines Inc.	3.35M	53.85	63.60M	-0.90	0.00
Ampio Pharmaceuticals Inc.	N/A	0.00	10.67M	-0.23	0.00

Table 1 shows the gross revenue, earnings per share and valuation for VBI Vaccines Inc. and Ampio Pharmaceuticals Inc.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

	Net Margins	Return on Equity	Return on Assets
VBI Vaccines Inc.	-1,898.51%	0%	0%
Ampio Pharmaceuticals Inc.	0.00%	-489.2%	381%

Analyst Ratings

VBI Vaccines Inc. and Ampio Pharmaceuticals Inc. Ratings and Recommendations are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
VBI Vaccines Inc.	0	0	1	3.00
Ampio Pharmaceuticals Inc.	0	0	0	0.00

VBI Vaccines Inc.’s upside potential is 386.49% at a $9 consensus price target.

Institutional and Insider Ownership

Roughly 55.46% of VBI Vaccines Inc. shares are owned by institutional investors while 24.5% of Ampio Pharmaceuticals Inc. are owned by institutional investors. Insiders owned 11.91% of VBI Vaccines Inc. shares. On the other hand, insiders owned about 0.5% of Ampio Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
VBI Vaccines Inc.	8.29%	17.37%	20.25%	-2.97%	-48.69%	22.5%
Ampio Pharmaceuticals Inc.	5.89%	36.92%	8.61%	8.68%	-68.31%	73.4%

For the past year VBI Vaccines Inc. was less bullish than Ampio Pharmaceuticals Inc.

Summary

Ampio Pharmaceuticals Inc. beats VBI Vaccines Inc. on 6 of the 10 factors.

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. The company also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants. In addition, it is developing CMV vaccine program, which is in Phase I clinical trials for the prevention of human cytomegalovirus infection; and for glioblastoma multiforme, which is in preclinical testing stage. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.